Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash from Operations (2016 - 2025)

Ironwood Pharmaceuticals' Cash from Operations history spans 16 years, with the latest figure at 74575000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 390.17% year-over-year to 74575000.0; the TTM value through Dec 2025 reached 127044000.0, up 22.69%, while the annual FY2025 figure was 127044000.0, 22.69% up from the prior year.
  • Cash from Operations for Q4 2025 was 74575000.0 at Ironwood Pharmaceuticals, up from 47583000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 80171000.0 in Q1 2023 and bottomed at 15068000.0 in Q2 2025.
  • The 5-year median for Cash from Operations is 48075500.0 (2021), against an average of 47483900.0.
  • The largest YoY upside for Cash from Operations was 390.17% in 2025 against a maximum downside of 145.03% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 64568000.0 in 2021, then increased by 22.63% to 79182000.0 in 2022, then crashed by 54.74% to 35834000.0 in 2023, then plummeted by 57.54% to 15214000.0 in 2024, then skyrocketed by 390.17% to 74575000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Cash from Operations are 74575000.0 (Q4 2025), 47583000.0 (Q3 2025), and 15068000.0 (Q2 2025).